Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L5 pseudogene 13 (RPL5P13) is a human processed pseudogene derived from the ribosomal protein L5 (RPL5) gene. Unlike RPL5, which encodes a structural protein of the 60S ribosomal subunit with vital roles in protein synthesis and some regulatory processes, RPL5P13 does not produce a functional protein. Pseudogenes like RPL5P13 are genomic sequences similar to known genes but are non-functional due to mutations or lack of regulatory elements. There is currently no evidence suggesting a unique biological function, disease association, or utility as a therapeutic target for RPL5P13[1][2][4]. Key distinction: Information about clinical significance, drug targets, or biological roles refers to the genuine protein-coding gene *RPL5*, not to RPL5P13, which is a non-coding and non-functional pseudogene[1][2][4].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L5 pseudogene 13 (RPL5P13).